Package Integrates PrimePCR™ Workflow and Offers Powerful New Analysis Options
Hercules, CA — September 4, 2012 — Bio-Rad Laboratories, Inc., today announced the availability of its CFX Manager 3.0 software for real-time PCR data acquisition and analysis. By integrating with Bio-Rad’s new PrimePCR™ assays and panels, enhancing its user interface, and adding new data analysis tools, CFX Manager 3.0 now offers researchers a complete, user-friendly solution for gene expression analysis that covers everything from run setup to generating publication-quality figures.
Most real-time PCR system software involves numerous steps to get runs started and requires data export or Web upload for advanced data analysis. CFX Manager 3.0 combines streamlined run setup and sophisticated data analysis in one software package.
Key benefits of CFX Manager 3.0 include:
- Quick run start: intuitive navigation, a new startup wizard, and a streamlined interface let users start collecting data with just a few clicks
- Integrated PrimePCR workflow: fully integrated workflow for running and analyzing data files generated using PrimePCR assays
- Guided gene expression analysis: guided plate setup wizard creates a gene expression analysis–compatible layout to assist users with experimental setup
- Extraction of more information: data plotting options that are particularly well-suited for large data sets include volcano plots, clustergrams, heat maps, and scatter plots
CFX Manager 3.0 is compatible with the CFX96™, CFX96 Touch™, CFX Connect™, CFX384™, CFX384 Touch™, and MiniOpticon™ real-time PCR detection systems.
For further details about CFX Manager 3.0, please visit http://www.bio-rad.com/cfxmanagersoftware.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Richard Kurtz
Bio-Rad Laboratories, Inc.
510-741-5638
Richard_Kurtz@bio-rad.com
Ken Li
Chempetitive Group
312-997-2436 x 109
kli@chempetitive.com